Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation...
Deals
Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. (“JunCell Biologics”) released its prospectus, announcing its intention to list...
Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
Relation Therapeutics Limited announced a multi‑program strategic collaboration with Novartis AG (NYSE: NVS) to discover...
Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership
OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A/S (NASDAQ: ZEAL)...
D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its subsidiary Chongqing Yaopharma...
Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) has granted Nanjing King-friend Biochemical Pharmaceutical Co., Ltd....
Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development
Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership...
Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership
Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly‑owned subsidiary Nova Pneuma Inc. (NPI)...
Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market
Zhaoke Ophthalmology (HKG: 6622) announced it has granted TSH Biopharm (TW-8432) exclusive rights to register,...
Shanghai Pharma X842 Deal Termination with Sinorda
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...
Mirxes XtalPi AI Platform Targets Asian GI Cancers
Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...
Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal
Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:...
OTR Therapeutics Series-A Raises $100M for Neurology Pipeline
OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...
Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform
Sanofi (NASDAQ: SNY) announced the completion of its $1.6 billion acquisition of Vicebio, first announced in...
Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient
Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...
Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...
Bio-Sincerity UCAS R&D Center Pharma Synthesis
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...
Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough
Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...
Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization
Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...